CSIMarket Company Name, Ticker, Industry, else..



Worst Performing Stocks In Major Pharmaceutical Preparations Industry During This Current Quarter Q3 Of 2024


 1 Day   Week  Current Month of September  30 Days 
Current Quarter Q3 of 2024  90 Days    Ytd    12 Months 
 

Shares improved by 8.88% on average, in Major Pharmaceutical Preparations Industry during this current quarter q3 of 2024.

Here are the Worst performing stocks in Major Pharmaceutical Preparations Industry.




MRK

$115.39

$-14.0600 -10.86%
This Quarter Q3 of 2024


MRK

$115.39

$-14.0600 -10.86%



Merck and Co Inc

Merck And Co Inc stock went down -10.86% during this current quarter q3 of 2024.


Merck and Co Inc operates primarily as a research-intensive pharmaceutical company, engaging in the development, manufacturing, and marketing of prescription drugs and vaccines worldwide. The company focuses on discovering innovative solutions to address unmet medical needs across various therapeutic areas, collaborating with academic institutions and conducting clinical trials to evaluate the efficacy and safety of their products. Merck and Co Inc also holds a strong commitment to the well-being of patients and aims to contribute to global healthcare by delivering high-quality, affordable medications.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 294,136.659 mill. $ 62,480.000 mill. $ 13,752.000 mill. 2,549 mill. 21.24 Y/Y 7.16 %
Market Cap. Revenues TTM Net Income TTM

$ 294,136.659 mill.
$ 62,480.000 mill.


$ 13,752.000 mill.
Employees Shares Outstanding P/E

68,000
2,549 mill.
21.24
Revenue Growth Income Growth

MRQ Y/Y 7.16 %
MRQ Y/Y - %


OGN

$20.18

$-0.7800 -3.72%
This Quarter Q3 of 2024


OGN

$20.18

$-0.7800 -3.72%



Organon and Co

Organon And Co shares went down -3.72% during this current quarter q3 of 2024.


Organon and Co*s business model revolves around developing and manufacturing pharmaceutical products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5,218.508 mill. $ 6,346.000 mill. $ 1,000.000 mill. 259 mill. 5.20 Y/Y -0.06 %
Market Cap. Revenues TTM Net Income TTM

$ 5,218.508 mill.
$ 6,346.000 mill.


$ 1,000.000 mill.
Employees Shares Outstanding P/E

9,300
259 mill.
5.20
Revenue Growth Income Growth

MRQ Y/Y -0.06 %
MRQ Y/Y -19.42 %


PFE

$29.505

$-0.0450 -0.15%
This Quarter Q3 of 2024


PFE

$29.505

$-0.0450 -0.15%



Pfizer Inc

Pfizer Inc shares went down -0.15% during this current quarter q3 of 2024.


Pfizer Inc operates as a global pharmaceutical company, focused on discovering, developing, manufacturing, and marketing innovative medicines. Its business model revolves around investing in research and development to create a diverse portfolio of therapies across various therapeutic areas. Leveraging its scale, Pfizer aims to commercialize these products globally and drive growth through strategic alliances and collaborations with other industry players.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 168,060.480 mill. $ 55,642.000 mill. $ -2,565.000 mill. 5,696 mill. - Y/Y 4.31 %
Market Cap. Revenues TTM Net Income TTM

$ 168,060.480 mill.
$ 55,642.000 mill.


$ -2,565.000 mill.
Employees Shares Outstanding P/E

79,000
5,696 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 4.31 %
MRQ Y/Y -97.95 %


CTLT

$59.91

$4.4400 8.00%
This Quarter Q3 of 2024


CTLT

$59.91

$4.4400 8.00%



Catalent Inc

Catalent Inc shares improved 8.00% during this current quarter q3 of 2024.


Catalent Inc*s business model is based on providing advanced delivery technologies and development solutions for pharmaceutical, biotechnology, and consumer health companies. They offer a range of services including drug development, manufacturing, packaging, and supply chain capabilities. Their focus is on helping their clients bring innovative and life-saving products to market efficiently and effectively.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 10,848.286 mill. $ 4,381.000 mill. $ -1,043.000 mill. 181 mill. - Y/Y 23.32 %
Market Cap. Revenues TTM Net Income TTM

$ 10,848.286 mill.
$ 4,381.000 mill.


$ -1,043.000 mill.
Employees Shares Outstanding P/E

19,000
181 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 23.32 %
MRQ Y/Y - %


LLY

$905.26

$73.5000 8.84%
This Quarter Q3 of 2024


LLY

$905.26

$73.5000 8.84%



Eli Lilly And Company

Eli Lilly And Company stock increased 8.84% during this current quarter q3 of 2024.


Eli Lilly and Company operates as a pharmaceutical company, primarily focused on researching, developing, manufacturing, and marketing prescription drugs across various therapeutic areas.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 818,536.092 mill. $ 38,922.800 mill. $ 7,342.200 mill. 904 mill. 111.43 Y/Y 35.98 %
Market Cap. Revenues TTM Net Income TTM

$ 818,536.092 mill.
$ 38,922.800 mill.


$ 7,342.200 mill.
Employees Shares Outstanding P/E

35,000
904 mill.
111.43
Revenue Growth Income Growth

MRQ Y/Y 35.98 %
MRQ Y/Y 68.27 %


ABT

$116.36

$13.1300 12.72%
This Quarter Q3 of 2024


ABT

$116.36

$13.1300 12.72%



Abbott Laboratories

Abbott Laboratories stock improved 12.72% during this current quarter q3 of 2024.


Abbott Laboratories operates as a diversified healthcare company with a broad portfolio of products. Their business model is centered around developing and manufacturing various health-related products, including pharmaceuticals, medical devices, nutritional products, and diagnostic technologies. They aim to serve a wide range of healthcare sectors globally by providing innovative solutions that improve the quality of patients* lives.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 203,764.163 mill. $ 40,725.000 mill. $ 5,557.000 mill. 1,751 mill. 36.63 Y/Y 4.00 %
Market Cap. Revenues TTM Net Income TTM

$ 203,764.163 mill.
$ 40,725.000 mill.


$ 5,557.000 mill.
Employees Shares Outstanding P/E

113,000
1,751 mill.
36.63
Revenue Growth Income Growth

MRQ Y/Y 4.00 %
MRQ Y/Y -5.31 %


JNJ

$166.79

$20.8200 14.26%
This Quarter Q3 of 2024


JNJ

$166.79

$20.8200 14.26%



Johnson and Johnson

Johnson And Johnson stock improved 14.26% during this current quarter q3 of 2024.


Johnson & Johnson operates as a multinational healthcare company with a diversified model. They develop, manufacture, and sell a broad range of pharmaceutical, medical devices, and consumer goods. Their business is focused on improving the health and well-being of people worldwide through innovation, research, and strategic acquisitions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 403,965.380 mill. $ 86,576.000 mill. $ 38,018.000 mill. 2,422 mill. 11.00 Y/Y -12.08 %
Market Cap. Revenues TTM Net Income TTM

$ 403,965.380 mill.
$ 86,576.000 mill.


$ 38,018.000 mill.
Employees Shares Outstanding P/E

141,700
2,422 mill.
11.00
Revenue Growth Income Growth

MRQ Y/Y -12.08 %
MRQ Y/Y -8.90 %


BMY

$48.655

$7.4150 17.98%
This Quarter Q3 of 2024


BMY

$48.655

$7.4150 17.98%



Bristol myers Squibb Company

Bristol Myers Squibb Company stock improved 17.98% during this current quarter q3 of 2024.


Bristol Myers Squibb Company is a pharmaceutical firm that operates on a research and development-driven business model, focused on discovering, developing, and delivering innovative medicines to treat various diseases. The company collaborates with academic institutions, government organizations, and other pharmaceutical companies to advance their portfolio of therapeutics and improve patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 98,482.410 mill. $ 46,509.000 mill. $ -6,528.000 mill. 2,024 mill. - Y/Y 8.69 %
Market Cap. Revenues TTM Net Income TTM

$ 98,482.410 mill.
$ 46,509.000 mill.


$ -6,528.000 mill.
Employees Shares Outstanding P/E

32,200
2,024 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 8.69 %
MRQ Y/Y -18.92 %


ABBV

$196.3309

$30.8909 18.67%
This Quarter Q3 of 2024


ABBV

$196.3309

$30.8909 18.67%



Abbvie Inc

Abbvie Inc shares improved 18.67% during this current quarter q3 of 2024.


Abbvie Inc operates primarily as a global biopharmaceutical company. Its business model centers around researching, developing, manufacturing, and commercializing advanced therapies and medications focusing on critical areas like immunology, oncology, neuroscience, virology, and more. By leveraging its expertise and capabilities, Abbvie aims to improve patient outcomes, address unmet medical needs, and provide value to its stakeholders in the healthcare industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 347,702.024 mill. $ 55,000.000 mill. $ 5,350.000 mill. 1,771 mill. 65.34 Y/Y 4.31 %
Market Cap. Revenues TTM Net Income TTM

$ 347,702.024 mill.
$ 55,000.000 mill.


$ 5,350.000 mill.
Employees Shares Outstanding P/E

50,000
1,771 mill.
65.34
Revenue Growth Income Growth

MRQ Y/Y 4.31 %
MRQ Y/Y -32.26 %



 1 Day   Week  Current Month of September  30 Days 
Current Quarter Q3 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com